Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
Phase 3
Completed
- Conditions
- Crohn's Disease
- Registration Number
- NCT00032786
- Lead Sponsor
- Biogen
- Brief Summary
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderate to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie natalizumab's inhibition of α4β1 and α4β7 integrins in Crohn's Disease?
How does natalizumab's efficacy in maintaining Crohn's remission compare to anti-TNF agents like infliximab?
Which biomarkers correlate with response to natalizumab in fistulizing or stricturing Crohn's subtypes?
What are the long-term safety risks of natalizumab in Crohn's patients, particularly PML incidence and monitoring strategies?
How do integrin receptor antagonists like natalizumab compare to vedolizumab in Crohn's disease therapeutic outcomes?